Antibodies

25 Jan 2008 KRAS Gene Status May Impact Vectibix(TM) (Panitumumab) Efficacy and Patient Reported Outcomes in Advanced Colorectal Cancer Patients
24 Jan 2008 Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R))
22 Jan 2008 CytoFab(TM) phase 2 programme in severe sepsis commenced byAstraZeneca
22 Jan 2008 Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
18 Jan 2008 ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
16 Jan 2008 MorphoSys Discloses GM-CSF as Target of MOR103 Program
16 Jan 2008 New Study Reports Enbrel(R) (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents
15 Jan 2008 BioInvent and Genentech Initiate Phase I Clinical Trial for BI-204, a potential treatment for cardiovascular conditions associated with atherosclerosis
15 Jan 2008 Progenics Initiates Phase 2 Clinical Trials for PRO 140, a Novel HIV Antibody Therapy
15 Jan 2008 Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
15 Jan 2008 ZymoGenetics Announces Special Protocol Assessment for Atacicept in General SLE
14 Jan 2008 FDA Approves TYSABRI(R) For The Treatment Of Moderate-To-Severe Crohn's Disease
09 Jan 2008 TRACON Pharmaceuticals Announces Dosing of Initial Three Cancer Patients in a Phase 1 Clinical Trial with TRC105, a Human Chimeric Antibody
09 Jan 2008 Anthera Pharmaceuticals Acquires the Worldwide Rights to a BAFF Inhibitor for the Treatment of Lupus and Other Autoimmune Diseases
09 Jan 2008 Medarex Announces Allowance of Investigational New Drug Application for Wholly Owned Fully Human Anti-CD70 Antibody, MDX-1411
08 Jan 2008 Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to Ophthotech
07 Jan 2008 Seattle Genetics Earns Milestone Payment from Initiation of SGN-40 Phase Ib Clinical Trial in Combination with Rituxan for Non-Hodgkin Lymphoma
04 Jan 2008 Genmab Announces HuMax-CD32B Pre-Clinical Program
03 Jan 2008 Crucell Enters Agreement with Sanofi Pasteur for Next-generation Biologicals against Rabies
03 Jan 2008 ImmunoGen, Inc. Expands Pipeline of Targeted Anticancer Compounds
03 Jan 2008 Expanded Labeling for MabCampath(R) in Europe
30 Dec 2007 MorphoSys Files Clinical Trial Application to Initiate First Phase 1 Clinical Study of its MOR103 Program
22 Dec 2007 Elan and Wyeth Dose First Patient in North America in Phase 3 Program for Bapineuzumab (AAB-001) in Alzheimer's Disease
21 Dec 2007 Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
21 Dec 2007 Fresenius Biotech applies for the marketing authorization of the trifunctional antibody Removab (R) for the treatment of malignant ascites

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top